4 recruiting, 1 not yet recruiting. 3 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow B Cell Acute Lymphoblastic Leukemia (B-ALL): new trials by email Literature Review of B Cell Acute Lymphoblastic Leukemia (B-ALL) trials Research Report on B Cell Acute Lymphoblastic Leukemia (B-ALL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) Nutrition Intervention, Exercise intervention - Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Not applicable | Recruiting | University of Chicago | 20 | 2025-05-12 | 2025-06-19 |
| Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2 - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 3000 | 2025-03-03 | 2025-08-26 |
| Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1800 | 2025-01-03 | 2026-07-23 |
| Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19) - B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Stephan Grupp MD PhD | 115 | 2022-09-20 | 2026-05-26 |
Burkitt Lymphoma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Lymphoma, B-Cell (1)
DNA Virus Infections (5) · Epstein-Barr Virus Infections (5) · Hemic and Lymphatic Diseases (5) · Herpesviridae Infections (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Infections (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Tumor Virus Infections (5) · Virus Diseases (5)
Dexamethasone (2) · Methotrexate (2) · Vincristine (2) · blinatumomab (2) · Antibiotic Prophylaxis (1) · Asparaginase (1) · Cyclophosphamide (1) · Cytarabine (1) · Daunorubicin (1) · Diet Therapy (1) · Immunoglobulins (1) · Prednisone (1) · venetoclax (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · Assistance Publique - Hôpitaux de Paris (1) · Stephan Grupp MD PhD (1) · University of Chicago (1)
China (2) · Hong Kong (2) · United States (2)
Xiaofan Zhu, MD (2) · Allison Barz Leahy, MD (1) · Stephan Grupp, MD,PhD (1) · Wendy Stock (1)